List of articles with "Multiple Myeloma"

ASH 2025 Myeloma Insights

ASH 2025 Myeloma Insights

United States Orlando Clinical Trials Multiple Myeloma ASH 2025
TECVAYLI® and DARZALEX FASPRO®

TECVAYLI® and DARZALEX FASPRO®

United States Orlando Multiple Myeloma TECVAYLI® DARZALEX FASPRO®
Tec-Dara Combination Therapy

Tec-Dara Combination Therapy

USA Orlando Multiple Myeloma Daratumumab Teclistamab
IASO Bio's CAR-T Therapy Update

IASO Bio's CAR-T Therapy Update

China Shanghai CAR-T therapy Multiple Myeloma IASO Bio
Leads Biolabs LBL-034 Data

Leads Biolabs LBL-034 Data

USA Leads Biolabs Orlando Multiple Myeloma LBL-034
IBI3003 Initial Results

IBI3003 Initial Results

China Suzhou Multiple Myeloma Innovent IBI3003
Long-term Success of CARVYKTI®

Long-term Success of CARVYKTI®

USA Johnson & Johnson Orlando Multiple Myeloma CARVYKTI
Gintemetostat Clinical Data

Gintemetostat Clinical Data

USA Orlando K36 Therapeutics Multiple Myeloma Gintemetostat
Darzalex Approval News

Darzalex Approval News

Japan Johnson & Johnson Tokyo Multiple Myeloma DARZALEX
DARZALEX Faspro® Approved

DARZALEX Faspro® Approved

USA San Diego Halozyme Therapeutics Multiple Myeloma DARZALEX FASPRO
Multiple Myeloma Future

Multiple Myeloma Future

USA Austin Immunotherapy Multiple Myeloma DataM Intelligence
Dual Therapy for Myeloma

Dual Therapy for Myeloma

Japan Tokyo Multiple Myeloma TECVAYLI Tarvey
Daratumumab Data

Daratumumab Data

Japan Tokyo Multiple Myeloma Daratumumab
Turby® in Myeloma

Turby® in Myeloma

Japan Johnson & Johnson Tokyo Multiple Myeloma Turby®
Teclistamab Study Highlights

Teclistamab Study Highlights

Japan Tokyo Multiple Myeloma Teclistamab Janssen Pharmaceuticals
Survival with TECVAYLI & DARZALEX

Survival with TECVAYLI & DARZALEX

USA Multiple Myeloma DARZALEX FASPRO Raritan TECVAYLI
TECVAYLI® & DARZALEX FASPRO® Results

TECVAYLI® & DARZALEX FASPRO® Results

USA Toronto Multiple Myeloma TECVAYLI® DARZALEX FASPRO®
K36's KTX-1001 Update

K36's KTX-1001 Update

United States Cambridge KTX-1001 K36 Therapeutics Multiple Myeloma
CARsgen Zevor-cel Update

CARsgen Zevor-cel Update

China Shanghai Multiple Myeloma CARsgen Zevor-cel
KTX-1001 Update

KTX-1001 Update

United States Cambridge KTX-1001 K36 Therapeutics Multiple Myeloma
HaemaLogiX Award Win

HaemaLogiX Award Win

Australia Sydney CAR-T therapy Multiple Myeloma HaemaLogiX
HaemaLogiX Awarded

HaemaLogiX Awarded

Australia Sydney CAR-T therapy Multiple Myeloma HaemaLogiX
Tarbey® Injection Released

Tarbey® Injection Released

Japan Johnson & Johnson Tokyo Multiple Myeloma Tarbey®
Multiple Myeloma Insights

Multiple Myeloma Insights

United States Multiple Myeloma Merck Manuals Rahway Health Awareness
DVRd Therapy for Myeloma

DVRd Therapy for Myeloma

Japan Tokyo Multiple Myeloma Daratumumab DVRd Therapy
Tarbey® Approved

Tarbey® Approved

Japan Johnson & Johnson Tokyo Multiple Myeloma Tarbey®
SKY92 Transforms Myeloma Care

SKY92 Transforms Myeloma Care

United States San Diego Multiple Myeloma SkylineDx SKY92
Promising ISB 2001 Results

Promising ISB 2001 Results

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
ISB 2001 Efficacy

ISB 2001 Efficacy

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
J&J New Myeloma Treatment

J&J New Myeloma Treatment

USA Chicago Johnson & Johnson Multiple Myeloma JNJ-79635322
CARVYKTI® Long-Term Remission

CARVYKTI® Long-Term Remission

United States Chicago Johnson & Johnson Multiple Myeloma CARVYKTI
DARZALEX FASPRO® Success

DARZALEX FASPRO® Success

USA Chicago Johnson & Johnson Multiple Myeloma DARZALEX FASPRO
Promising ISB 2001 Data

Promising ISB 2001 Data

USA New York Multiple Myeloma ISB 2001 TRIgnite-1 study
ISB 2001 in Multiple Myeloma

ISB 2001 in Multiple Myeloma

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
FDA Backs DARZALEX FASPRO®

FDA Backs DARZALEX FASPRO®

United States Johnson & Johnson Multiple Myeloma Raritan, NJ DARZALEX FASPRO®
FDA Fast-Track for ISB 2001

FDA Fast-Track for ISB 2001

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
FDA Fast Track for ISB 2001

FDA Fast Track for ISB 2001

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
FDA Fast Track for ISB 2001

FDA Fast Track for ISB 2001

USA New York Multiple Myeloma ISB 2001 Ichnos Glenmark Innovation
FDA Fast Track for ISB 2001

FDA Fast Track for ISB 2001

USA New York Multiple Myeloma Ichnos Glenmark ISB 2001
DARZALEX® Approval

DARZALEX® Approval

None Halozyme Multiple Myeloma DARZALEX
Transforming Myeloma Care

Transforming Myeloma Care

None Multiple Myeloma DARZALEX Janssen
Myeloma Market Growth

Myeloma Market Growth

None CAR-T therapy Multiple Myeloma DARZALEX
SkylineDx Unveils SKY92 Test

SkylineDx Unveils SKY92 Test

Netherlands Multiple Myeloma Rotterdam SkylineDx SKY92
KPG-818 IND Approval

KPG-818 IND Approval

China Hefei Multiple Myeloma Kangpu Biopharmaceuticals KPG-818
XPOVIO® Approved in Taiwan

XPOVIO® Approved in Taiwan

Taiwan Taipei XPOVIO Multiple Myeloma Antengene
New Antibody for Myeloma

New Antibody for Myeloma

USA Multiple Myeloma AbbVie North Chicago Simcere Zaiming
Innovative Cancer Partnership

Innovative Cancer Partnership

United States Multiple Myeloma AbbVie North Chicago Simcere Zaiming
AbbVie and Simcere Team Up

AbbVie and Simcere Team Up

United States Multiple Myeloma AbbVie North Chicago Simcere Zaiming
Promising Data for Lisaftoclax

Promising Data for Lisaftoclax

USA San Diego Ascentage Pharma Multiple Myeloma Lisaftoclax
CAR T-Cell Study Insights

CAR T-Cell Study Insights

China Shanghai Multiple Myeloma IASO Bio CAR T-Cell

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.